Recurrent ovarian cancer as chronic disease.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012008:Recurrence; D019772:Topotecan / Q000627:therapeutic use; D000068878:Trastuzumab; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D003841:Deoxycytidine; D005047:Etoposide; D019772:Topotecan; D004317:Doxorubicin; D000068878:Trastuzumab; D000093542:Gemcitabine